Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of ROS-Related Gene TNFSF13B as a Diagnostic Biomarker in Tuberculosis: Insights from WGCNA.

Infection and drug resistance·2026
Same author

PDZK1 disassembles HER2-HSP90 complexes to promote ubiquitin-mediated HER2 degradation and overcome therapy resistance.

Journal of advanced research·2026
Same author

Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial.

JAMA oncology·2026
Same author

Comparative extracellular and intracellular anti-Mycobacterium tuberculosis activity of three tanshinones from Salvia miltiorrhiza and oral cryptotanshinone efficacy in mice.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Spatial hepatology: Decoding liver zonation for metabolic and regenerative therapeutics (Review).

International journal of molecular medicine·2026
Same author

Targeting ZNF570 activates ferroptosis to reverse tamoxifen resistance in ER + breast cancer cells.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same journal

The WEE1 inhibitor azenosertib broadly enhances efficacy of antibody-drug conjugates with topoisomerase I and microtubule inhibitor payloads.

iScience·2026
Same journal

Na<sub>2</sub>CO<sub>3</sub>-assisted oxygen-alkali recyclable cellulose separation/pulping technology of straw and silicon controllable migration.

iScience·2026
Same journal

Local global feature enhanced transformer with attention pruning for precise medical image segmentation.

iScience·2026
Same journal

hSpindly dynamics modulate spindle assembly checkpoint signaling, promoting resistance to mitotic inhibitors.

iScience·2026
Same journal

Naive CD4<sup>+</sup> T cells synthesize a hyaluronan-rich glycocalyx that is diminished following activation.

iScience·2026
Same journal

STRAP promotes hepatocellular carcinoma progression through activation of an STRAP/Wnt-β-catenin/STRAP positive feedback loop.

iScience·2026
See all related articles
  1. Home
  3. A Multi-center Clinical Evaluation On First-in-class Rop-based Igra For Tuberculosis Diagnosis.
  1. Home
  3. A Multi-center Clinical Evaluation On First-in-class Rop-based Igra For Tuberculosis Diagnosis.

Related Experiment Video

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

A multi-center clinical evaluation on first-in-class ROP-based IGRA for tuberculosis diagnosis.

Qiang Li1,2, Yulin Huang3, Lihui Nie1

  • 1Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.

Iscience
|June 15, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

A new tuberculosis (TB) diagnostic, recombinant overlapping peptide (ROP)-TB, shows high agreement with existing interferon-gamma release assays (IGRAs). This ROP-TB technology offers improved detection of latent and drug-resistant TB strains.

Keywords:
Health sciencesMedicineRespiratory medicine

More Related Videos

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Related Experiment Videos

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

Area of Science:

  • Immunology
  • Infectious Diseases
  • Biotechnology

Background:

  • Tuberculosis (TB) is a major global infectious disease killer.
  • Current interferon-gamma release assays (IGRAs) use pooled peptides, hindering large-scale production and quality control.
  • Recombinant overlapping peptide (ROP) technology offers a potential solution.

Purpose of the Study:

  • To evaluate the diagnostic performance of ROP-TB, a novel IGRA reagent.
  • To compare ROP-TB with the established T-SPOT.TB assay in a multi-center clinical trial.
  • To assess ROP-TB's ability to detect latent and drug-resistant TB.

Main Methods:

  • Development and evaluation of ROP-TB technology.
  • Multi-center clinical trial in China (September 2021-August 2022).
  • Comparison of ROP-TB with T-SPOT.TB using concordance, sensitivity, and specificity metrics.

    • Main Results:

    • ROP-TB demonstrated high concordance with T-SPOT.TB (overall agreement 94.49%, κ = 0.889).
    • ROP-TB achieved a sensitivity of 88.03% and specificity of 76.79%.
    • ROP-TB elicited stronger immune responses in latent and drug-resistant TB cases.

    Conclusions:

    • ROP-TB is a viable auxiliary diagnostic and screening tool for TB.
    • ROP-TB performance is comparable to T-SPOT.TB.
    • ROP-TB shows enhanced potential for detecting latent and resistant TB strains.